View Author
patient study treatment blood expression group leukemia survival response month myeloid leukemia cancer cytogenetic result transplantation analysis table trial tumor myeloma t-cell therapy myeloid outcome donor cell transplantation abnormality disease range chemotherapy resistance value marker prognostic number center phase factor signi marrow netherland cr rate imatinib effect cycle induction score protein level adult figure cytarabine relapse randomized change allogeneic -833 hovon psc -833 chromosome reactivation grade diagnosis ratio autologou polymorphism cytogenetic abnormalities signi ficantly neuropathy university recovery 60 years sonneveld p ebv-lpd t cells hospital function allo-sct multidrug thalidomide
10 Most Recent Publications
|
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group
(Article)
Thielen, N. Holt, B. van der Schipperus, M.R. Schattenberg, A.V.M.B. Marwijk Kooy, R. van Smit, W.M. Chu, I.W.T. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Verhoef, G.E.G. Ammerlaan, R.A.H.M. Sonneveld, P. Janssen, J.J.W.M. Deenik, W. Falkenburg, J.H.F. Kersten, M.J. Sinnige, H. |
2013-04-10
|
|
Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients
(Article)
Wils, E-J. Holt, B. van der Broers, A.E.C. Posthumus-van Sluijs, S.J. Gratama, J-W. Braakman, E. Cornelissen, J.J. |
2011-12-01
|
|
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients
(Article)
Corthals, S.L. Kuiper, R. Johnson, D.C. Sonneveld, P. Hajek, R. Holt, B. van der Magrangeas, F. Goldschmidt, H. Morgan, G. Avet-Loiseau, H. |
2011-11-01
|
|
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: Prognostic markers and potential targets for immunotherapy
(Article)
Duin, M. van Broyl, A. Sahota, S.S. Sonneveld, P. Knegt, Y. de Goldschmidt, H. Richardson, P.G. Hop, W.C.J. Holt, B. van der Joseph-Pietras, D. Mulligan, G. Neuwirth, R. |
2011-11-01
|
|
MicroRNA signatures characterize multiple myeloma patients
(Article)
Corthals, S.L. Sun, S.M. Zweegman, S. Jongen-Lavrencic, M. Sonneveld, P. Kuiper, R. Knegt, Y. de Broyl, A. Holt, B. van der Beverloo, H.B. Peeters, J.K. Jarari, L. Lokhorst, H.M. |
2011-11-01
|
|
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: Results of the HOVON 76 Trial
(Article)
Kneppers, E. Holt, B. van der Bruijnen, C.P. Emmelot, M. Sonneveld, P. Lokhorst, H.M. Mutis, T. Minnema, M.C. Kersten, M.J. Zweegman, S. Meijer, E. Huls, G. Cornelissen, J.J. Janssen, J.J. Huisman, C. Cornelisse, P.B. |
2011-09-01
|
|
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment
(Article)
Graan, A-J.M. de Teunissen, S.F. Beijnen, J.H. Mathijssen, R.H.J. Vos, F.Y.F.L. de Loos, W.J. Schaik, R.H.N. van Jongh, F.E. de Alphen, R.J. van Holt, B. van der Verweij, J. Seynaeve, C.M. |
2011-08-20
|
|
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
(Article)
Rijneveld, A.W. Holt, B. van der Wijermans, P. Wittebol, S. Spoelstra, F.M. Dekker, A.W. Ossenkoppele, G.J. Willemze, R. Cornelissen, J.J. Daenen, S.M.G.J. Biemond, B.J. de Weerdt, O. Muus, P. Maertens, J. Mattijssen, V. Demuynck, H. Legdeur, M.C.J.C. |
2011-06-07
|
|
Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia
(Article)
Lodewyck, T. Oudshoorn, M. Willemze, R. Löwenberg, B. Verdonck, L.F. Meijering, E. Cornelissen, J.J. Holt, B. van der Petersen, E. Spierings, E. von dem Borne, P.A. Schattenberg, A.V.M.B. Allebes, W.A. Groenendijk-Sijnke, M. Duinhouwer, L. |
2011-06-01
|
|
The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas
(Article)
Rayman, N. Lam, K.H. Holt, B. van der Koss, C. Leeuwen, J. van Budel, L.M. Mulder, A.H. Sonneveld, P. Delwel, H.R. |
2011-06-01
|
